<DOC>
	<DOCNO>NCT01054339</DOCNO>
	<brief_summary>This study evaluate safety efficacy recombinant adeno-associated virus vector express alpha-1 antitrypsin patient alpha-1 antitrypsin deficiency . Three group three subject receive study drug intramuscular injection , progressively large dose second third group . Funding Sources - FDA OOPD NIH NHLBI</brief_summary>
	<brief_title>Safety &amp; Efficacy Study rAAV1-CB-hAAT Alpha-1 Antitrypsin Deficiency</brief_title>
	<detailed_description>The study non-randomized , open-label , multi-center , sequential , three-arm , Phase 2 clinical trial evaluate safety efficacy administration rAAV1-CB-hAAT vector administer IM injection . Each participant receive rAAV1-CB-hAAT single occasion . Three group three subject receive rAAV1-CB-hAAT dosage level 6 x 10e11 vg/kg , 1.9 x 10e12 vg/kg 6 x 10e12 vg/kg IM injection . Subjects group 1 receive total 10 IM injection distribute across single muscle site , subject group 2 receive total 32 IM injection distribute across three muscle site , subject group 3 receive 100 IM injection distribute across 10 muscle site . Each injection give volume 1.35 mL , appropriate vector concentration achieve desire total vector dose , injection density administration site ( nine IM injection per 4 cm2 skin surface area ) injection density well tolerate previous Phase 1 clinical trial rAAV1-CB-hAAT . Safety monitor evaluation adverse event , hematology clinical chemistry parameter , histological examination muscle biopsy , measurement serum antibody AAT . Efficacy measure evaluation serum concentration M-specific AAT total AAT serum AAT phenotype determine isoelectric focusing gel . Additional information collect include presence vector blood semen , change serum anti-AAV antibody titer , change T cell response AAV AAT .</detailed_description>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<criteria>1 . Have diagnosis AATdeficiency , define serum AAT level le 11 µM phenotype genotype either homozygous PI*Z compound heterozygous consist PI*Z another allele know associated disease 2 . Be least 18 75 year age 3 . Have FEV1 &gt; 25 % predict value ( post bronchodilator ) 4 . Weigh ≤ 90 kg 5 . Not receive AAT augmentation therapy currently past 3 month , plan begin therapy least 12 month administration rAAV1CBhAAT 6 . Be willing discontinue aspirin , aspirincontaining product , drug may alter platelet function , 7 day prior dose , resume earlier 24 hour dose administer 7 . Have acceptable laboratory parameter 8 . For female childbearing potential : A negative pregnancy test ( urine serum ) screen baseline ( within 2 day administration study agent ) Agreement consistently use barrier contraception ( condom , diaphragm cervical cap spermicide ) another form contraception ( e.g . intrauterine device hormonal contraception ) screen visit 12 month administration rAAV1CBhAAT , sexual activity could lead pregnancy 9 . For male reproductive potential , agreement consistently use barrier contraception ( condoms spermicide ) 12 month administration rAAV1CBhAAT , sexual activity could lead pregnancy , 10 . Provide sign informed consent screen 1 . Prior receipt AAV gene therapy product 2 . Use anticoagulant antiplatelet agent within 7 day prior study agent administration 3 . History immune response human AAT augmentation therapy indicate clinical history adverse immune response infusion and/or decrease therapeutic effect combination documentation serum antiAAT antibodies 4 . Use acute oral intravenous antibiotic therapy respiratory infection within 28 day prior study agent administration ( longterm maintenance chronic suppressive oral antibiotic , antibiotic nonrespiratory indication , allow ) 5 . Use oral systemic corticosteroid within 28 day prior study agent administration 6 . Use investigational agent , immunosuppressive drug ( ) , within 3 month prior enrollment 7 . For female childbearing potential , positive pregnancy test screen baseline ( within 2 day rAAV1CBhAAT administration ) 8 . Females breast feed 9 . Have significant abnormal EKG find screen and/or cardiac disease ( e.g . recent myocardial infarction CHF ) within past 6 month 10 . Have pulmonary edema pulmonary embolism within past 6 month 11 . Have history immunodeficiency medical condition lead investigator believe participant comply protocol requirement may place participant unacceptable risk participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Alpha-1 antitrypsin deficiency</keyword>
	<keyword>Adeno-associated virus vector</keyword>
	<keyword>AAV</keyword>
	<keyword>Gene therapy</keyword>
	<keyword>Human gene transfer</keyword>
</DOC>